Previous close | 157.21 |
Open | 162.24 |
Bid | 159.00 x 900 |
Ask | 160.70 x 1400 |
Day's range | 156.62 - 162.20 |
52-week range | 117.08 - 391.57 |
Volume | |
Avg. volume | 1,142,658 |
Market cap | 39.107B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 3.46 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 02 Jun 2022 |
1y target est | N/A |
This isn't shaping up to be a banner week for BioNTech (NASDAQ: BNTX). The bellwether coronavirus stock took it on the chin Monday and was being similarly battered by investors Tuesday because of post-earnings analyst price target cuts. Following second-quarter results that disappointed many investors, several analysts recalibrated their takes on BioNTech stock Tuesday.
Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.